Multivalent Influenza Nanoparticle Vaccines
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 62/787,980, filed Jan 3, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,278,612 | Multivalent Influenza Nanoparticle Vaccines In force · High confidence | Novavax, Inc. | In force | High confidence | ||
| US 11,896,662 | Multivalent Influenza Nanoparticle Vaccines In force · High confidence | Novavax, Inc. | In force | High confidence | ||
| Application 18/403,182 | Multivalent Influenza Nanoparticle Vaccines Abandoned Abandoned Jul 24, 2025 | Novavax, Inc. | Abandoned | Abandoned Jul 24, 2025 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Novavax, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.